RxDoctor Payments Data

Jayesh Madrecha, DO

Family Medicine · Kenner, LANPI 1831502020

Payments from drug & device makers

$454in general payments, 2019–2025

Across 19 payments — averaging $23.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$223
  • Pfizer$67
  • Organon$38
  • Exact Sciences$35
  • AstraZeneca$23
  • Johnson & Johnson$20
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$454100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$454 in reported general payments places this provider in the 40th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$20,387
Medicare patients
83
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$110,800
JardianceEmpagliflozin69$104,755
MounjaroTirzepatide61$86,266
TrulicityDulaglutide35$51,148
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$43,658
EliquisApixaban46$42,471
DescovyEmtricitabine/Tenofov Alafenam12$26,512
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr37$23,494
FarxigaDapagliflozin Propanediol16$12,698
XareltoRivaroxaban15$12,328
Repatha SureclickEvolocumab13$12,143
NexiumEsomeprazole Magnesium20$9,322
Atorvastatin Calcium694$6,190
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$4,211
Amlodipine-ValsartanAmlodipine Besylate/Valsartan56$3,703

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$19$137,41496 claims
Novo NordiskOzempic$14$110,80073 claims
PfizerEliquis$67$42,47146 claims
GileadDescovy$223$26,51212 claims
AstraZenecaFarxiga, Nexium, Symbicort$23$25,51650 claims
Johnson & JohnsonXarelto$20$12,32815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Kenner

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →